Pharmaceutical - Cardio-vascular, Servier

Filter

Current filters:

Cardio-vascularServier

Popular Filters

EMA PRAC’s recommendations to reduce risk of heart problems with ivabradine

09-11-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a…

AmgenCardio-vascularEuropeivabradinePharmaceuticalProcoralanRegulationServier

Servier to appeal EC fine over perindopril

Servier to appeal EC fine over perindopril

11-07-2014

French privately-held drugmaker Servier has said it will appeal before the European Union Court of Justice…

Cardio-vascularEuropeFinancialLegalPerindoprilperindoprilPharmaceuticalServier

Ivabradine and CV events in angina patients under review in Australia

Ivabradine and CV events in angina patients under review in Australia

23-06-2014

Australian pharma regulator the Therapeutic Goods Administration (TGA) is reviewing new information regarding…

AustraliaCardio-vascularCoralanivabradinePharmaceuticalRegulationServier

Servier Canada collaborates in two research projects

Servier Canada collaborates in two research projects

17-02-2014

Two major projects in clinical research conducted by Canada’s Montreal Heart Institute (MHI) and the…

CanadaCardio-vascularFinancialNorth AmericaPharmaceuticalResearchServier

Amgen's US deal with Servier cleared

13-08-2013

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Amgen gains rights to Servier's heart drugs ivabradine and S38844

10-07-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

XOMA transfers perindopril franchise rights to Symplmed

08-07-2013

California, USA-based XOMA Corp (Nasdaq: XOMA) says it has transferred US development and commercialization…

Cardio-vascularLicensingMergers & AcquisitionsperindoprilPharmaceuticalServierSymplmedXOMA Corp

XOMA's perindopril and amlodipine FDC meets primary endpoint in Ph III blood pressure trial

23-11-2012

California, USA-based XOMA Corp (Nasdaq: XOMA) says the 837-patient Phase III PATH trial (Perindopril…

Amlodipine BesylateCardio-vascularLicensingNorth AmericaperindoprilPharmaceuticalResearchServierXOMA Corp

UK NICE draft guidance backs Servier's Procoralan for chronic heart failure

06-08-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

Cardio-vascularEuropePharmaceuticalPricingProcoralanRegulationServier

EU Commission focus now on Servier and others re-perindopril antitrust issues

31-07-2012

The European Commission has informed French independent pharmaceutical company Servier and several of…

Cardio-vascularEuropeGenericsLegalMarkets & MarketingMylan LaboratoriesPatentsperindoprilPharmaceuticalServierTeva Pharmaceutical Industries

EMA calls for curbs on trimetazidine-containing and tolperisone medicines

24-06-2012

The European Medicines Agency on Friday recommended restricting the use of trimetazidine-containing medicines…

Cardio-vascularEuropeNeurologicalPharmaceuticalRegulationServiertolperisonetrimetazidineVestrel

XOMA acquires US rights to perindopril franchise

18-01-2012

California, USA-based XOMA Corp (Nasdaq: XOMA) says it has acquired US rights to the perindopril franchise…

AceonCardio-vascularMergers & AcquisitionsperindoprilPharmaceuticalServierXOMA Corp

Parexel

Parexel

Back to top